- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
GeoVax Joins Joint Development to Develop Lassa Fever Vaccine
GeoVax Labs announced that in collaboration with a variety of medical groups is collaborating for the advanced development of a preventive vaccine against Lassa hemorrhagic fever virus.
GeoVax Labs (OTCQB:GOVX) announced that in collaboration with a variety of medical groups is collaborating for the advanced development of a preventive vaccine against Lassa hemorrhagic fever virus.
As quoted in the press release:
GeoVax previously announced that its LASV vaccine candidate, GEO-LM01, provided 100% protection after single immunization, to mice infected with a lethal dose of a LASV reassortant. The intent of the three-way collaboration with TSRI and IHV is to evaluate additional LASV vaccine candidates to elucidate involvement of humoral and cellular arms of immunity in protection against LASV infections.
Farshad Guirakhoo, PhD, GeoVax’s Chief Scientific Officer, commented, “We are pleased to expand our collaboration with IHV, and to now work with Professor Erica Ollmann Saphire, PhD at TSRI as well, an expert in the structure of LASV and other viral hemorrhagic fever viruses. Our MVA-VLP vaccine platform is well-suited for quickly generating various candidates and testing them using a LASV reassortant challenge model developed at IHV.”
“The structural studies from the Saphire lab will help broaden and strengthen humoral immune responses to LASV. Fortunately, the MVA platform can easily accommodate these new constructs,” noted Maria Salvato, PhD, Professor of Medicine, Institute of Human Virology, University of Maryland School of Medicine.
Click here to read the full press release.
Source: www.marketwired.com
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.